JP2010053136A5

JP2010053136A5 -

Download PDF

Info

Publication number: JP2010053136A5
Authority: JP; Japan
Prior art keywords: peptide; tat; peptides; jnk; cell
Prior art date: 2009-11-30
Legal status : Withdrawn

Application number

JP2009272904A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010053136A (ja

Filing date

2009-11-30

Publication date

2011-02-10

2002-06-07 Priority claimed from US10/165,250 external-priority patent/US20030108539A1/en

2009-11-30 Application filed filed Critical

2010-03-11 Publication of JP2010053136A publication Critical patent/JP2010053136A/ja

2011-02-10 Publication of JP2010053136A5 publication Critical patent/JP2010053136A5/ja

Status Withdrawn legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 description 410
102000004196 processed proteins & peptides Human genes 0.000 description 188
210000004027 cell Anatomy 0.000 description 141
238000000034 method Methods 0.000 description 111
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 109
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 95
150000001413 amino acids Chemical group 0.000 description 92
239000012825 JNK inhibitor Substances 0.000 description 84
229940118135 JNK inhibitor Drugs 0.000 description 83
235000001014 amino acid Nutrition 0.000 description 52
229940024606 amino acid Drugs 0.000 description 52
150000007523 nucleic acids Chemical class 0.000 description 46
102000039446 nucleic acids Human genes 0.000 description 44
108020004707 nucleic acids Proteins 0.000 description 44
230000000694 effects Effects 0.000 description 43
HRMVIAFZYCCHGF-BMCUWHFPSA-N am111 peptide Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H]([C@H](C)O)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(O)=O)C(C)C)C1=CC=CC=C1 HRMVIAFZYCCHGF-BMCUWHFPSA-N 0.000 description 36
108090000623 proteins and genes Proteins 0.000 description 36
108010060110 D-JNKI-1 Proteins 0.000 description 35
210000002569 neuron Anatomy 0.000 description 31
102100023132 Transcription factor Jun Human genes 0.000 description 30
229920001184 polypeptide Polymers 0.000 description 30
238000011282 treatment Methods 0.000 description 30
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 28
230000030833 cell death Effects 0.000 description 26
241000699670 Mus sp. Species 0.000 description 25
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 25
230000014509 gene expression Effects 0.000 description 25
230000004913 activation Effects 0.000 description 24
230000006378 damage Effects 0.000 description 24
238000002474 experimental method Methods 0.000 description 24
235000018102 proteins Nutrition 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 23
230000027455 binding Effects 0.000 description 22
230000000975 bioactive effect Effects 0.000 description 22
230000005764 inhibitory process Effects 0.000 description 22
239000012634 fragment Substances 0.000 description 21
230000026731 phosphorylation Effects 0.000 description 21
238000006366 phosphorylation reaction Methods 0.000 description 21
230000003492 excitotoxic effect Effects 0.000 description 20
230000002401 inhibitory effect Effects 0.000 description 20
208000035475 disorder Diseases 0.000 description 19
239000013598 vector Substances 0.000 description 19
206010061216 Infarction Diseases 0.000 description 18
101710149951 Protein Tat Proteins 0.000 description 18
230000006907 apoptotic process Effects 0.000 description 18
241000700159 Rattus Species 0.000 description 17
208000014674 injury Diseases 0.000 description 17
239000000243 solution Substances 0.000 description 17
102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 16
101001046660 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 16
101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 16
101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 16
230000016273 neuron death Effects 0.000 description 16
102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 15
210000004556 brain Anatomy 0.000 description 15
239000003814 drug Substances 0.000 description 15
231100000318 excitotoxic Toxicity 0.000 description 15
208000028867 ischemia Diseases 0.000 description 15
206010011878 Deafness Diseases 0.000 description 14
241000282414 Homo sapiens Species 0.000 description 14
239000003431 cross linking reagent Substances 0.000 description 14
230000010370 hearing loss Effects 0.000 description 14
231100000888 hearing loss Toxicity 0.000 description 14
208000016354 hearing loss disease Diseases 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
230000007574 infarction Effects 0.000 description 14
239000007924 injection Substances 0.000 description 14
238000002347 injection Methods 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
101001046656 Homo sapiens C-Jun-amino-terminal kinase-interacting protein 2 Proteins 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 13
208000027418 Wounds and injury Diseases 0.000 description 13
230000003115 biocidal effect Effects 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
230000000302 ischemic effect Effects 0.000 description 13
230000001537 neural effect Effects 0.000 description 13
239000000523 sample Substances 0.000 description 13
229940124597 therapeutic agent Drugs 0.000 description 13
102100022287 C-Jun-amino-terminal kinase-interacting protein 2 Human genes 0.000 description 12
102000019145 JUN kinase activity proteins Human genes 0.000 description 12
230000004224 protection Effects 0.000 description 12
201000006474 Brain Ischemia Diseases 0.000 description 11
206010008120 Cerebral ischaemia Diseases 0.000 description 11
206010008118 cerebral infarction Diseases 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
230000004927 fusion Effects 0.000 description 11
210000004153 islets of langerhan Anatomy 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
201000010099 disease Diseases 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
102000040430 polynucleotide Human genes 0.000 description 10
108091033319 polynucleotide Proteins 0.000 description 10
239000002157 polynucleotide Substances 0.000 description 10
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
239000000758 substrate Substances 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
241000725303 Human immunodeficiency virus Species 0.000 description 9
108091000080 Phosphotransferase Proteins 0.000 description 9
230000009471 action Effects 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 9
230000005779 cell damage Effects 0.000 description 9
208000037887 cell injury Diseases 0.000 description 9
229940127089 cytotoxic agent Drugs 0.000 description 9
239000000284 extract Substances 0.000 description 9
239000000499 gel Substances 0.000 description 9
238000001415 gene therapy Methods 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
102000020233 phosphotransferase Human genes 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
206010008089 Cerebral artery occlusion Diseases 0.000 description 8
101150033452 Elk1 gene Proteins 0.000 description 8
150000008575 L-amino acids Chemical class 0.000 description 8
101100287693 Rattus norvegicus Kcnh4 gene Proteins 0.000 description 8
101100287705 Rattus norvegicus Kcnh8 gene Proteins 0.000 description 8
238000010586 diagram Methods 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 7
108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
239000005090 green fluorescent protein Substances 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
238000000021 kinase assay Methods 0.000 description 7
230000007774 longterm Effects 0.000 description 7
210000004940 nucleus Anatomy 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
230000000770 proinflammatory effect Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
238000012546 transfer Methods 0.000 description 7
102000029816 Collagenase Human genes 0.000 description 6
108060005980 Collagenase Proteins 0.000 description 6
206010010904 Convulsion Diseases 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 6
102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 6
239000004365 Protease Substances 0.000 description 6
102100027584 Protein c-Fos Human genes 0.000 description 6
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 6
102000040945 Transcription factor Human genes 0.000 description 6
108091023040 Transcription factor Proteins 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
210000001627 cerebral artery Anatomy 0.000 description 6
108091006116 chimeric peptides Proteins 0.000 description 6
229960002424 collagenase Drugs 0.000 description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
230000034994 death Effects 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000012139 lysis buffer Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
125000006850 spacer group Chemical group 0.000 description 6
230000001629 suppression Effects 0.000 description 6
208000024827 Alzheimer disease Diseases 0.000 description 5
241000972773 Aulopiformes Species 0.000 description 5
108010051109 Cell-Penetrating Peptides Proteins 0.000 description 5
102000020313 Cell-Penetrating Peptides Human genes 0.000 description 5
239000004971 Cross linker Substances 0.000 description 5
150000008574 D-amino acids Chemical class 0.000 description 5
206010011903 Deafness traumatic Diseases 0.000 description 5
102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 5
102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 5
206010015150 Erythema Diseases 0.000 description 5
101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 5
101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 5
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 5
208000023105 Huntington disease Diseases 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 5
206010030113 Oedema Diseases 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
239000011324 bead Substances 0.000 description 5
208000029028 brain injury Diseases 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
231100000321 erythema Toxicity 0.000 description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
210000002768 hair cell Anatomy 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000001802 infusion Methods 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000004112 neuroprotection Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000002265 prevention Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000010410 reperfusion Effects 0.000 description 5
235000019515 salmon Nutrition 0.000 description 5
229960005322 streptomycin Drugs 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
102000007469 Actins Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
206010012289 Dementia Diseases 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
229920001917 Ficoll Polymers 0.000 description 4
102000005720 Glutathione transferase Human genes 0.000 description 4
108010070675 Glutathione transferase Proteins 0.000 description 4
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 4
206010021143 Hypoxia Diseases 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 4
108010002352 Interleukin-1 Proteins 0.000 description 4
-1 L-form amino acids Chemical class 0.000 description 4
108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 4
102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 4
208000018737 Parkinson disease Diseases 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000012190 activator Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
210000000805 cytoplasm Anatomy 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 4
210000003027 ear inner Anatomy 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005865 ionizing radiation Effects 0.000 description 4
230000002427 irreversible effect Effects 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000003449 preventive effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000013615 primer Substances 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
235000013930 proline Nutrition 0.000 description 4
238000003753 real-time PCR Methods 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
230000008685 targeting Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
238000013519 translation Methods 0.000 description 4
230000008733 trauma Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000001262 western blot Methods 0.000 description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102100039556 Galectin-4 Human genes 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
108010018525 NFATC Transcription Factors Proteins 0.000 description 3
102000002673 NFATC Transcription Factors Human genes 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
208000030886 Traumatic Brain injury Diseases 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
229940126575 aminoglycoside Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
230000006931 brain damage Effects 0.000 description 3
231100000874 brain damage Toxicity 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000003727 cerebral blood flow Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
231100000063 excitotoxicity Toxicity 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000004807 localization Effects 0.000 description 3
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
230000009223 neuronal apoptosis Effects 0.000 description 3
210000002985 organ of corti Anatomy 0.000 description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
230000011664 signaling Effects 0.000 description 3
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
229940048086 sodium pyrophosphate Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
150000003573 thiols Chemical group 0.000 description 3
230000009529 traumatic brain injury Effects 0.000 description 3
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
239000004474 valine Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
206010014498 Embolic stroke Diseases 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010063602 Exposure to noise Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000019149 MAP kinase activity proteins Human genes 0.000 description 2
108040008097 MAP kinase activity proteins Proteins 0.000 description 2
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
208000021642 Muscular disease Diseases 0.000 description 2
201000009623 Myopathy Diseases 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
241000009328 Perro Species 0.000 description 2
241000288906 Primates Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000004075 alteration Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012412 chemical coupling Methods 0.000 description 2
238000010382 chemical cross-linking Methods 0.000 description 2
239000013000 chemical inhibitor Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
210000003618 cortical neuron Anatomy 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000006353 environmental stress Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
210000003128 head Anatomy 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000007659 motor function Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000027405 negative regulation of phosphorylation Effects 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000007512 neuronal protection Effects 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
150000003148 prolines Chemical class 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
235000019419 proteases Nutrition 0.000 description 2
230000002633 protecting effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000009751 type B pancreatic cell apoptotic process Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
VZZPYUKWXDLMGI-UHFFFAOYSA-N 1,6-diisothiocyanatohexane Chemical compound S=C=NCCCCCCN=C=S VZZPYUKWXDLMGI-UHFFFAOYSA-N 0.000 description 1
AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical group O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 1
DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
IPJGAEWUPXWFPL-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=CC(N2C(C=CC2=O)=O)=C1 IPJGAEWUPXWFPL-UHFFFAOYSA-N 0.000 description 1
KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
RLFPCLMBTQOMLI-UHFFFAOYSA-N 2-iodo-n-[2-[(2-iodoacetyl)amino]ethyl]acetamide Chemical compound ICC(=O)NCCNC(=O)CI RLFPCLMBTQOMLI-UHFFFAOYSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
NQXOUNOJWFMRLG-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoic acid;pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1.C1=CC(CCCC(=O)O)=CC=C1N1C(=O)C=CC1=O NQXOUNOJWFMRLG-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
208000011594 Autoinflammatory disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
101710105206 C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
102100033620 Calponin-1 Human genes 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
206010048964 Carotid artery occlusion Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
239000012623 DNA damaging agent Substances 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
101001059644 Homo sapiens MAP kinase-activating death domain protein Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
206010024558 Lip oedema Diseases 0.000 description 1
208000007021 Lipedema Diseases 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
102100028822 MAP kinase-activating death domain protein Human genes 0.000 description 1
241001467552 Mycobacterium bovis BCG Species 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108091005461 Nucleic proteins Chemical group 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
229930195708 Penicillin V Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101100341613 Rattus norvegicus Mapk8ip1 gene Proteins 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101150050957 TNKS gene Proteins 0.000 description 1
101710192266 Tegument protein VP22 Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010043647 Thrombotic Stroke Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000004004 carotid artery internal Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
229960001585 dicloxacillin Drugs 0.000 description 1
YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
102000007656 ets-Domain Protein Elk-1 Human genes 0.000 description 1
108010032461 ets-Domain Protein Elk-1 Proteins 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000834 fixative Substances 0.000 description 1
108700025906 fos Genes Proteins 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012817 gel-diffusion technique Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
210000003897 hepatic stem cell Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
238000012759 hoechst 33342 nuclear staining Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000054579 human MAPK8IP1 Human genes 0.000 description 1
102000056438 human MAPK8IP2 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000002134 immunopathologic effect Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000008676 import Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000010039 intracellular degradation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000009525 mild injury Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
230000019581 neuron apoptotic process Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
101150015886 nuc-1 gene Proteins 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
230000006548 oncogenic transformation Effects 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960001019 oxacillin Drugs 0.000 description 1
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000021401 pellet diet Nutrition 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
229940056367 penicillin v Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
108010091718 peptide L Proteins 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000002824 peroxisome Anatomy 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010079892 phosphoglycerol kinase Proteins 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000012342 propidium iodide staining Methods 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

JP2009272904A 2002-06-07 2009-11-30 Ｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤 Withdrawn JP2010053136A (ja)